CoChat
Sign Up
Cited by 369Pulmonary Hypertension Research and TreatmentsNitric Oxide and Endothelin EffectsVascular Anomalies and Treatments

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension

Xu, Weiling, Kaneko, F. Takao, Zheng, Shuo, Comhair, Suzy A. A., Janocha, Allison J., Goggans, Tannishia, Thunnissen, Frederik B. J. M., Farver, Carol, Hazen, Stanley L., Jennings, Constance, Dweik, Raed A., Arroliga, Alejandro C., Erzurum, Serpil C.·2004·The FASEB Journal
DOI 10.1096/fj.04-2317fje
Open this paper in CoChat — free account

Abstract

Pulmonary arterial hypertension (PAH), a fatal disease of unknown etiology characterized by impaired regulation of pulmonary hemodynamics and vascular growth, is associated with low levels of pulmonary nitric oxide (NO). Based upon its critical role in mediating vasodilation and cell growth, decrease of NO has been implicated in the pathogenesis of PAH. We evaluated mechanisms for low NO and pulmonary hypertension, including NO synthases (NOS) and factors regulating NOS activity, i.e. the substrate arginine, arginase expression and activity, and endogenous inhibitors of NOS in patients with PAH and healthy controls. PAH lungs had normal NOS I–III expression, but substrate arginine levels were inversely related to pulmonary artery pressures. Activity of arginase, an enzyme that regulates NO biosynthesis through effects on arginine, was higher in PAH serum than in controls, with high‐level arginase expression localized by immunostaining to pulmonary endothelial cells. Further, pulmonary artery endothelial cells derived from PAH lung had higher arginase II expression and produced lower NO than control cells in vitro. Thus, substrate availability affects NOS activity and vasodilation, implicating arginase II and alterations in arginine metabolic pathways in the pathophysiology of PAH.

Overview

Integrity signals

Registry

Crossref · 10.1096/fj.04-2317fje

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 75 references

Cited by

Sorted by citations

See all 369

Related

Metadata

Authors
Xu, W., Kaneko, F. T., Zheng, S., Comhair, S. A. A., Janocha, A. J., Goggans, T., Thunnissen, F. B. J. M., Farver, C., Hazen, S. L., Jennings, C., Dweik, R. A., Arroliga, A. C., & Erzurum, S. C.
Affiliations
  • Cleveland Clinic (US)
  • Department of Pathology Canisius Wihelmina Ziekenhuis Nijmegen The Netherlands
ORCID
Venue
The FASEB Journal
Publisher
Wiley
Published
2004-09-13
Volume
18
Issue
14
Pages
1746-1748
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
DOI
10.1096/fj.04-2317fje
OpenAlex
W2116905957
Cited by
369
References
75
Citations by year
2026: 4 · 2025: 5 · 2024: 14 · 2023: 10 · 2022: 10 · 2021: 18 · 2020: 12 · 2019: 12 · 2018: 16 · 2017: 23 · 2016: 13 · 2015: 17 · 2014: 21 · 2013: 27 · 2012: 13
FWCI
16.61
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (HL 60917, HL 04265, HL076491)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
Keywords
pulmonary arterial hypertension, arginase II, nitric oxide production, nitric oxide synthase, arginine metabolism, endothelial cells, pulmonary artery endothelium, vasodilation, pulmonary hypertension pathogenesis, nitric oxide synthase inhibitors
MeSH terms
Arginase, Blood Pressure, Cells, Cultured, Endothelium, Vascular, Humans, Hypertension, Pulmonary, Nitric Oxide, Pulmonary Artery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review